Replies to post #86519 on Anavex Life Sciences Corp (AVXL)

[ExtremelyBullishZig]

In my opinion it is because they are actively seeking a dual therapy patent evident from the FDA interview with anavex in mid-December... Averaging data together would show synergy...

[BeingReal]

OhSay, I've been thinking the same thing..

Is there a reason that they could not explicitly state that patients were switched to monotherapy at the time of the last data release in December?

I would expect the details of dosage to be presented to the scientific community, and can't understand what reasons Dr. M would have in being vague. It's not what they presented, it's what they did not.

I wonder if it's just his style; he sees no reason to state what is not there. He presented results for A 2-73...period. Again, I would expect clarity on if and how the switch to mono therapy was achieved and how they track the impact of the change. Why are we still speculating about this? Could it be that no changes were made and it is simply time that was needed to improve patient results?

[McMagyar]

Great question..
Why not tell the world?
I think Anavex is as scared as the FDA!
We need a bigger boat!

[sokol]

I believe the decision to discontinue any other therapy of any patient participant in this or any trial must be a decision made by each patient and the patient's physician. Furthermore, it may be that this would need to be reported to the FDA. It is questionable whether anyone that is not the patient's physician would recommend that the patient discontinue an FDA approved drug prescribed by the patient's physician and take instead a mono-therapy that has not been approved by the FDA. I see serious implications in pursuing the path of "switching" a patient to an unapproved mono-therapy -- "efficacy" has not been established! Anavex would, in my opinion, be foolish to "switch" patients to the mono-therapy and announce it to the world as you say. Frankly, I do not think Anavex can legally do that. Moreover, I do not think a physician would risk "switching" a patient from an approved drug (SOC) to an unapproved drug!